Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 23.02.18 in Vol 7, No 1 (2018): Jan-Jun

This paper is in the following e-collection/theme issue:

Works citing "The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life"

Monique Josephine Mastboom, Rosa Planje, Michiel Adreanus van de Sande

Interact J Med Res 2018 (Feb 23); 7(1):e4 

According to Crossref, the following articles are citing this article (DOI 10.2196/ijmr.9325):

(note that this is only a small subset of citations)

  1. Cook NS, Landskroner K, Shah B, Walda S, Weiss O, Pallapotu V. Identification of Patient Needs and Preferences in Pigmented Villonodular Synovitis (PVNS) Using a Qualitative Online Bulletin Board Study. Advances in Therapy 2020;37(6):2813
    CrossRef
  2. Machado V, San-Julián M. Risk factors for early osteoarthritis in tenosynovial giant cell tumour. Revista Española de Cirugía Ortopédica y Traumatología (English Edition) 2020;64(3):199
    CrossRef
  3. Palmerini E, Longhi A, Donati DM, Staals EL. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. Expert Review of Anticancer Therapy 2020;20(6):441
    CrossRef
  4. Palmerini E, Longhi A, Donati D, Staals EL. Advances in treatment for tenosynovial giant cell tumors. Expert Opinion on Orphan Drugs 2018;6(12):753
    CrossRef
  5. Zhou L, Parmanto B. Development and Validation of a Comprehensive Well-Being Scale for People in the University Environment (Pitt Wellness Scale) Using a Crowdsourcing Approach: Cross-Sectional Study. Journal of Medical Internet Research 2020;22(4):e15075
    CrossRef
  6. Mastboom M, Staals E, Verspoor F, Rueten-Budde A, Stacchiotti S, Palmerini E, Schaap G, Jutte P, Aston W, Leithner A, Dammerer D, Takeuchi A, Thio Q, Niu X, Wunder J, van de Sande M. Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. Journal of Bone and Joint Surgery 2019;101(14):1309
    CrossRef
  7. Machado V, San-Julián M. Factores de riesgo para artrosis precoz en el tumor de células gigantes tenosinovial. Revista Española de Cirugía Ortopédica y Traumatología 2020;64(3):199
    CrossRef
  8. Quaresma MB, Portela J, Soares do Brito J. Open versus arthroscopic surgery for diffuse tenosynovial giant-cell tumours of the knee: a systematic review. EFORT Open Reviews 2020;5(6):339
    CrossRef
  9. Gelderblom H, de Sande MV. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncology 2020;16(29):2345
    CrossRef
  10. Verspoor FGM, Mastboom MJL, Hannink G, van der Graaf WTA, van de Sande MAJ, Schreuder HWB. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. The Bone & Joint Journal 2019;101-B(3):272
    CrossRef
  11. Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu EQ, Kwong WJ, Abraham JA. The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States. Journal of Occupational & Environmental Medicine 2021;63(4):e197
    CrossRef
  12. Van De Sande M, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, Stacchiotti S, Desai J, Wagner AJ, Alcindor T, Ganjoo K, Martín-Broto J, Wang Q, Shuster D, Gelderblom H, Healey JH. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Acta Orthopaedica 2021;92(4):493
    CrossRef
  13. Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Frontiers in Public Health 2021;9
    CrossRef
  14. Lopez-Bastida J, Aranda-Reneo I, Rodríguez-Sánchez B, Peña-Longobardo LM, Ye X, Laeis P, Fronk EM, Palmerini E, Leithner A, Van de Sande MAJ. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. Orphanet Journal of Rare Diseases 2021;16(1)
    CrossRef
  15. Popping S, Kall M, Nichols BE, Stempher E, Versteegh L, van de Vijver DA, van Sighem A, Versteegh M, Boucher C, Delpech V, Verbon A. Quality of life among people living with HIV in England and the Netherlands: a population-based study. The Lancet Regional Health - Europe 2021;8:100177
    CrossRef
  16. Miller EG, Woodward AL, Flinchum G, Young JL, Tabor HK, Halley MC. Opportunities and pitfalls of social media research in rare genetic diseases: a systematic review. Genetics in Medicine 2021;
    CrossRef
  17. Palmerini E, Staals EL. Treatment updates on tenosynovial giant cell tumor. Current Opinion in Oncology 2022;34(4):322
    CrossRef
  18. Stacchiotti S, Dürr HR, Schaefer I, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay J, Boye K, Broto J, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkcodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FM, Wagner A, Wiltink L, Stern S, Van de Sande M, Bauer S. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Cancer Treatment Reviews 2023;112:102491
    CrossRef
  19. Francisco R, Brasil S, Pascoal C, Jaeken J, Liddle M, Videira PA, dos Reis Ferreira V. The road to successful people-centric research in rare diseases: the web-based case study of the Immunology and Congenital Disorders of Glycosylation questionnaire (ImmunoCDGQ). Orphanet Journal of Rare Diseases 2022;17(1)
    CrossRef
  20. Healey JH, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, Stacchiotti S, Desai J, Wagner AJ, Alcindor T, Ganjoo K, Martín-Broto J, Wang Q, Shuster D, Gelderblom H, van de Sande M. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN. Clinical Orthopaedics & Related Research 2023;481(1):107
    CrossRef
  21. Tap WD, Healey JH. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor. Tumor Biology 2022;44(1):239
    CrossRef
  22. Monticelli M, Francisco R, Brasil S, Marques-da-Silva D, Rijoff T, Pascoal C, Jaeken J, Videira PA, dos Reis Ferreira V. Stakeholders’ views on drug development: the congenital disorders of glycosylation community perspective. Orphanet Journal of Rare Diseases 2022;17(1)
    CrossRef
  23. Lin F, Wilson K, Kwong WJ, Abraham JA. Understanding the Effect of Osteoarthritis on Surgical Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients With Tenosynovial Giant Cell Tumors. JAAOS: Global Research and Reviews 2023;7(5)
    CrossRef
  24. Lin F, Jacqueline Kwong W, Pan I, Ye X, Dai D, Tap W. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor. The Oncologist 2024;29(4):e535
    CrossRef
  25. Tap WD, Sharma MG, Vallee M, Smith BD, Sherman ML, Ruiz-Soto R, de Sande MV, Randall RL, Bernthal NM, Gelderblom H. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. Future Oncology 2024;20(10):593
    CrossRef
  26. Jiang Y, Sun X, Jiang M, Min H, Wang J, Fu X, Qi J, Yu Z, Zhu X, Wu Y. Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial. Frontiers in Public Health 2024;12
    CrossRef
  27. Dharmani C, Fofah O, Wang E, Salas M, Wooddell M, Tu N, Tse J, Near A, Tinoco G. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA. Future Oncology 2024;
    CrossRef